Learn more about ISENTRESS, a prescription HIV-1 medicine. See important risk info. Drug information on Raltegravir Tablet (chewable), tablet (film coated), granule for oral suspension for health care professionals. Drug information on Raltegravir for patients and consumers. side effects of raltegravir, read the drug label or package insert or talk to your health care provider.
|Published (Last):||1 July 2014|
|PDF File Size:||13.41 Mb|
|ePub File Size:||15.87 Mb|
|Price:||Free* [*Free Regsitration Required]|
Unknown if drug is removed by dialysis; avoid dosing before dialysis session. Effect of food Low fat AUC ratio: Renal raltegravir package insert No dosage adjustment required for any degree raltegravir package insert renal impairment Dialysis: Risks involved outweigh potential benefits.
OR Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Rhabdomyolysis Nervous system disorders: Share cases and questions with Physicians on Medscape consult. QL Quantity Limits Drugs that have quantity limits associated with each prescription. Either animal studies show no risk but raltegravir package insert studies not available or animal studies showed minor risks and human studies done and showed no risk. Raltegravir package insert Email Print Feedback Close.
Quantity Limits Drugs that have quantity psckage associated with each prescription. Animal studies show rltegravir and human studies not available or neither animal nor human studies done.
Most commonly, these are “preferred” on formulary brand drugs. Contact the applicable plan provider for the most current information.
Owing to inser potential for HIV transmission in HIV-negative infantsdeveloping viral resistance in HIV- positive infantsand adverse reactions in a breastfed infant, instruct mothers not raltegravir package insert breastfeed if they are imsert therapy.
The use of other active agents with raltegravir is associated with a greater likelihood of treatment response. Most commonly, these are “non-preferred” brand drugs or specialty prescription products. Use with caution if benefits outweigh risks. ST Step Therapy Drugs that have step therapy associated with each prescription.
Individual plans may vary raltegravir package insert formulary information changes.
Print with Office Info. Packsge Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription. Step Therapy Drugs that have step therapy associated with each prescription.
Formulary Formulary Patient Discounts. Controlled studies in pregnant women show no evidence of fetal risk. Most commonly, these are generic drugs. There is a pregnancy exposure registry that monitors pregnancy outcomes in women; raltegravir package insert providers are encouraged to register patients inssert calling the Antiretroviral Pregnancy Registry APR at 1- If you raltegravir package insert out, you will be required to enter your username and password the next time you visit.
To view formulary information first create a list of plans. Need a Curbside Consult?
European Medicines Agency – System/website unavailable
Significant – Monitor Closely. Not studied Isentress HD Safety and efficacy not established; administration is not recommended. Prior Authorization Drugs that require prior authorization. Dosing Considerations Combination regimen is based on safety, tolerability, pharmacokinetic parameters, and efficacy data through at least wk in a multicenter, open-label, noncomparative study in HIV-1 infected children and adolescents aged 4 wk to 18 yr Do not substitute chewable tablets or oral suspension for film-coated tablets; these are raltegravir package insert bioequivalent, and therefore, are not interchangeable Raltegdavir not switch between film-coated mg and mg tablet if prescribed dose is mg.
Chewable tablets contain phenylalanine, a component of aspartame Drug interactions overview Coadministration of raltegravir with drugs that inhibit UGT1A1 eg, rifampin may reduce plasma levels of raltegravir package insert see Dosage Modifications Coadministration with other strong inducers eg, carbamazepine, phenobarbital, phenytoin of drug metabolizing enzymes on raltegravir is unknown raltegravir package insert therefore not recommended.
Absorption Raltsgravir state Peak plasma concentration: In animal reproduction studies in rats and rabbits, no evidence of adverse developmental outcomes observed with oral administration raltegrabir organogenesis at doses that produced exposures up to approximately 4 times maximal recommended human dose MRHD of mg.
Severe, potentially life-threatening and fatal skin reactions reported; skin reactions include cases of Stevens-Johnson syndrome, hypersensitivity reaction and toxic epidermal necrolysis; immediately discontinue treatment raltegravir package insert severe hypersensitivity, severe rash, raltegravig rash with systemic symptoms or liver aminotransferase elevations develops and monitor clinical status, including liver ihsert closely.
This website also contains material raltegdavir by 3rd parties. Oral Administration May administer with or without raltegrwvir Do not substitute chewable tablets or oral suspension for film-coated tablets; raltegravir package insert are not bioequivalent, and therefore, are not interchangeable Film-coated tablet: Coadministration with drugs that are strong raotegravir raltegravir package insert UGT1A1 may result in raaltegravir plasma concentrations of raltegravir.
By clicking send, you acknowledge that you have permission to email the recipient with this information. Adding plans allows raltegravir package insert to compare formulary status to other drugs in the same class. Isentress, Isentress HD Classes: Brand and Other Names: Combination regimen is based on safety, tolerability, pharmacokinetic parameters, and efficacy data through at least wk in a multicenter, open-label, noncomparative study in HIV-1 infected children and adolescents aged 4 wk to 18 yr.
No data are available on presence of raltegravir package insert in human milk, effects on breastfed infant, or on milk production; when administered to lactating rats, raltegravir was present in milk. No dose adjustment raltegravir package insert Severe Child Pugh C: Available data from APR show no difference in rate of overall birth defects for raltegravir compared to background rate for major birth defects of 2.
The above information is provided for general informational and educational insrrt only. What would you like to print? Print this section Print the entire contents of.